A multicenter, double-blind, randomized, controlled study of patients with treatment-resistant schizophrenia treated with yokukansan for 12 weeks.

Published in: PCN reports : psychiatry and clinical neurosciences (2023)

Yokukansan is very safe and has clinical potential as a treatment for schizophrenia in combination with Western medicine.

Keyphrases